Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years.
Antibody
Genital
HPV
Oral
Persistence
Serology
Women
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
28 04 2022
28 04 2022
Historique:
received:
05
11
2020
accepted:
13
04
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
3
5
2022
Statut:
epublish
Résumé
The role of human papillomavirus (HPV) antibodies acquired through natural infection and their role in protection for subsequent cervical or oral HPV-carriage remains unclear. A total of 267 women, with a 36-months follow-up, from the Finnish Family HPV (FFHPV) study were evaluated to shed more light on persistent HPV-specific antibodies to genital or oral HPV-carriage, clearance or persistence during the three years follow-up. The type-specific seroprevalence for HPV genotypes 6, 11, 16, 18 and 45 in these women was assessed in relation to the detection of the same genotype or any HPV in their oral and genital samples. The following HPV serological outcomes where detected: being always seronegative, seroconversion or persistent seropositivity. Genital HPV16 infections were most prevalent at the end of the follow-up (24- and 36-month visit) among women who tested always seronegative for HPV16. No such associations between serology and HPV detection were established for the other HPV genotypes in the genital or oral samples. The development of long-term type-specific HPV 6,11,16,18 and 45 persistence (≥ 24 months) or clearance of the genital or oral infections was not different among the women with high HPV genotype specific antibody levels and those testing always HPV-seronegative. No significant role was disclosed for the acquired natural high-level- or persistent HPV antibodies as determinants of the genital or oral HPV infection outcomes in these young, non-vaccinated women.
Sections du résumé
BACKGROUND
The role of human papillomavirus (HPV) antibodies acquired through natural infection and their role in protection for subsequent cervical or oral HPV-carriage remains unclear.
METHODS
A total of 267 women, with a 36-months follow-up, from the Finnish Family HPV (FFHPV) study were evaluated to shed more light on persistent HPV-specific antibodies to genital or oral HPV-carriage, clearance or persistence during the three years follow-up. The type-specific seroprevalence for HPV genotypes 6, 11, 16, 18 and 45 in these women was assessed in relation to the detection of the same genotype or any HPV in their oral and genital samples. The following HPV serological outcomes where detected: being always seronegative, seroconversion or persistent seropositivity.
RESULTS
Genital HPV16 infections were most prevalent at the end of the follow-up (24- and 36-month visit) among women who tested always seronegative for HPV16. No such associations between serology and HPV detection were established for the other HPV genotypes in the genital or oral samples. The development of long-term type-specific HPV 6,11,16,18 and 45 persistence (≥ 24 months) or clearance of the genital or oral infections was not different among the women with high HPV genotype specific antibody levels and those testing always HPV-seronegative.
CONCLUSION
No significant role was disclosed for the acquired natural high-level- or persistent HPV antibodies as determinants of the genital or oral HPV infection outcomes in these young, non-vaccinated women.
Identifiants
pubmed: 35484584
doi: 10.1186/s12905-022-01717-x
pii: 10.1186/s12905-022-01717-x
pmc: PMC9052499
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141Informations de copyright
© 2022. The Author(s).
Références
BMC Infect Dis. 2014 Mar 03;14:120
pubmed: 24588945
Sex Transm Dis. 2010 Nov;37(11):706-14
pubmed: 20661178
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
PLoS Pathog. 2008 Jun 20;4(6):e1000091
pubmed: 18566657
PLoS One. 2015 Feb 02;10(2):e0116618
pubmed: 25642941
Eur J Oral Sci. 2018 Oct;126 Suppl 1:49-66
pubmed: 30178562
J Infect Dis. 2014 Aug 15;210(4):517-34
pubmed: 24610876
J Infect Dis. 2014 Aug 1;210(3):448-55
pubmed: 24569064
J Infect Dis. 2000 Jun;181(6):1911-9
pubmed: 10837170
Am J Epidemiol. 2008 Jul 15;168(2):123-37
pubmed: 18483125
J Gen Virol. 2011 Sep;92(Pt 9):2034-2046
pubmed: 21632564
J Immunol Methods. 2006 Feb 20;309(1-2):200-4
pubmed: 16406059
J Clin Microbiol. 2006 Feb;44(2):504-12
pubmed: 16455905
J Infect Dis. 2018 Jun 5;218(1):84-94
pubmed: 29718393
Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50
pubmed: 24189371
Lancet. 2007 Jun 30;369(9580):2161-2170
pubmed: 17602732
J Gen Virol. 2009 Jun;90(Pt 6):1515-1526
pubmed: 19264653
Infect Agent Cancer. 2010 Oct 20;5:19
pubmed: 20961432
J Infect Dis. 2016 May 1;213(9):1444-54
pubmed: 26690341
PLoS One. 2013;8(1):e53413
pubmed: 23301068